Intervention period
active malignancy
INFLUENZA A, APPENDIX, LIVER DISEASE, INFLUENZA
Trained kiosk staff conducted on‐site rapid molecular influenza testing (Abbott ID NOW, Abbott Laboratories, Lake Bluff, IL, USA), which detects and distinguishes between influenza A and B, and produces a result in 12 min, using nasal specimens collected from participants. Baloxavir (XOFLUZA, Genentech, San Francisco, CA, USA) was administered to all influenza‐positive participants aged ≥12 years. Study clinicians were available by phone to respond to questions or concerns that could not be directly addressed by the kiosk staff. For individuals who tested positive aged 3 months to 11 years, pregnant or breastfeeding, or adults with active malignancy, liver disease, or immunocompromised, a 5‐day treatment course of oseltamivir (TAMIFLU, Roche, Basel, Switzerland) was dispensed. All other individuals aged ≥12 years received a single dose of baloxavir (Appendix Participants with symptom onset < 48 h were eligible for the intervention as initiation of antiviral treatment is recommended within 48 h of influenza symptom onset for greatest clinical benefits.